Maria Ufniarska

Maria Ufniarska

Auto-generated profile, based on publicly available information

Maria Ufniarska

MD, Saint Adalbert Hospital in Gdańsk, aleja Jana Pawła II 50, 80-462 Gdańsk, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
TUTomasz Andrzej Ufniarski
Tomasz Andrzej Ufniarski
MUMaria Ufniarska
Maria Ufniarska
APAleksandra Piech
Aleksandra Piech
KPKarolina Pasierb
Karolina Pasierb
KPKarol Poplicha
Karol Poplicha
PUPatrycja Ucieklak
Patrycja Ucieklak
This narrative review examines whether Large Language Model (LLM)–based chatbots can help close the global mental health treatment gap while weighing their public-health risks. We synthesize peer-reviewed studies and relevant case reports to: (1) map the dimensions of the mental health treatment gap, (2) describe how recent LLM advances have changed chatbot capabilities, (3) explore how chatbots can address the dimensions of the gap, (4) evaluate evidence for clinical effectiveness, and (5) outline major safety, ethical, and policy concerns. Findings indicate that chatbots offer scalable, always-available, and low-cost support that can reduce barriers related to stigma, geographic and temporal access, affordability, and mental-health awareness. We found that the evidence supports chatbot interventions’ efficiency in small-to-moderate short-term reductions in depression and anxiety symptoms, while the long-term effects and use in other disorders remain largely unexplored. However, LLM chatbots also present clear risks: hallucinations and clinically inappropriate responses, amplification of stigma or bias, user dependence, and significant data-security vulnerabilities. Importantly, most widely used generalist LLMs lack rigorous clinical validation. We conclude that LLM chatbots are a persistent feature of the mental-health ecosystem whose benefits can be realized only with robust safety guardrails, transparent evaluation, integration into stepped-care pathways, and proactive regulation.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MGMartyna Grodzińska
Martyna Grodzińska
PSPiotr Sobkiewicz
Piotr Sobkiewicz
KPKarol Poplicha
Karol Poplicha
MUMaria Ufniarska
Maria Ufniarska
APAleksandra Piech
Aleksandra Piech
JUJarosław Ucieklak
Jarosław Ucieklak
Anorexia nervosa is a group of symptoms based on conscious restriction of food intake. Anorexia disrupts the body's homeostasis, so that the functioning of many organs is impaired. These dysfunctions involve the neuroendocrine system, the cardiovascular system, the skeletal system, the digestive system, and the reproductive system. Knowing the symptoms makes it possible to make an accurate diagnosis at an early stage of the disease. This is especially important given the increasing incidence and mortality rates. This article reviews the main clinical manifestations of AN. Attention is given to both pharmacotherapies and psychotherapy. The aim of the study: The purpose of this paper is to summarize the existing knowledge on mental anorexia nervosa. The article presents etiology, epidemiology, diagnosis, differentiation, clinical picture and treatment. The topic of eating disorders in pregnant women is also described. Material and method: In our article we used English databases such as PubMed and Google Scholar. We selected the articles according to key words such as eating disorders, osteoporosis, cardiomyopathy, hypoglycemia, psychotherapy, medical assessment, treatment. Conclusions: Eating disorders are a topic that unites many medical disciplines. The array of symptoms accompanying the disease clearly demonstrates the correlation of mental health with somatic health. Negative effects affect the skeletal system, neuroendocrine system, cardiovascular system, gastrointestinal system and reproductive system. Treatment is based on the use of pharmacotherapy, mainly using SSRI group drugs, as well as psychotherapy. A particularly appreciated current, among specialists, is cognitive-behavioral therapy.

11 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MUMaria Ufniarska
Maria Ufniarska
TUTomasz Andrzej Ufniarski
Tomasz Andrzej Ufniarski
APAleksandra Piech
Aleksandra Piech
KPKarolina Pasierb
Karolina Pasierb
KPKarol Poplicha
Karol Poplicha
PUPatrycja Ucieklak
Patrycja Ucieklak
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques, tau neurofibrillary tangles, and other pathological factors like neuroinflammation and oxidative stress. This review discusses the effectiveness of Lanacemab and Donanemab - new anti-amyloid monoclonal antibodies- for the treatment of early Alzheimer’s Disease. While no cure exists, current symptomatic treatments are complemented by emerging disease-modifying therapies (DMTs). Recent breakthroughs with anti-amyloid monoclonal antibodies, Lecanemab and Donanemab, show promise in slowing disease progression. Clinical trials like CLARITY-AD for Lecanemab and TRAILBLAZER-ALZ 2 for Donanemab demonstrated significant reductions in brain amyloid and a slowed cognitive and functional decline in early AD. Lecanemab selectively targets Aβ protofibrils, while Donanemab targets N-terminally truncated Aβ in plaques, both facilitating amyloid clearance. These DMTs, though associated with side effects like ARIA, mark a pivotal shift towards targeting underlying AD pathology, offering hope for more effective interventions and potentially preventive strategies, such as those explored in the TRAILBLAZER-ALZ 3 trial.

15 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
PKPatrycja Kardasz
Patrycja Kardasz
APAleksandra Piech
Aleksandra Piech
MGMartyna Grodzińska
Martyna Grodzińska
TUTomasz Andrzej Ufniarski
Tomasz Andrzej Ufniarski
MUMaria Ufniarska
Maria Ufniarska
PUPatrycja Ucieklak
Patrycja Ucieklak
Ulcerative colitis (UC) is a chronic inflammatory disease of the large intestine, often associated with significant impacts on patients' quality of life and public health systems. Traditional treatments, such as aminosalicylates, are not always effective, especially in moderate to severe cases. Etrasimod, a novel oral selective modulator of sphingosine-1-phosphate (S1P) receptors, offers an innovative therapeutic approach by regulating immune cell migration and reducing intestinal inflammation. This review explores the efficacy, safety, and potential role of Etrasimod in the treatment of UC. Recent clinical trials have demonstrated its significant effectiveness in both the induction and maintenance of remission in patients with moderately to severely active UC. The drug also shows a favorable safety and tolerability profile. These findings position Etrasimod as a promising alternative for patients who do not respond to standard therapies. As research progresses, Etrasimod may represent a step forward in the development of more targeted, disease-modifying treatments for ulcerative colitis. Aim of the study: This review investigates Etrasimod’s role in ulcerative colitis treatment, in particular focusing on its mechanism of action, clinical efficacy, and safety. It seeks to determine whether it could serve as an alternative for patients resistant to conventional treatments. Methodology: A literature review was conducted using PubMed, Google Scholar, and clinical trial registries. Summary: Ulcerative colitis treatment remains challenging, with many patients experiencing limited benefits from existing therapies. Etrasimod, a selective modulator targeting S1P receptors, has demonstrated efficacy in induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. Findings from clinical trials, particularly ELEVATE UC 12, 40 JAPAN and 52, suggest its potential in ulcerative colitis treatment. Further long-term studies are needed to confirm its benefits.

19 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KPKarolina Pasierb
Karolina Pasierb
APAleksandra Piech
Aleksandra Piech
TUTomasz Andrzej Ufniarski
Tomasz Andrzej Ufniarski
MGMartyna Grodzińska
Martyna Grodzińska
MUMaria Ufniarska
Maria Ufniarska
PUPatrycja Ucieklak
Patrycja Ucieklak
Chronic upper respiratory conditions encompass a wide range of diseases including allergic rhinitis (AR), non-allergic rhinitis (NAR), and nasal polyps (NP) affecting a significant proportion of the general population, and posing a substantial burden on the healthcare system. Upper respiratory symptoms impair nasal airflow, worsen quality of life and negatively impact daily functioning and productivity. In both amateurs and professional athletes, nasal symptoms diminish athletic performance and competitive ability. Furthermore, such symptoms discourage recreational exercisers from regular physical activity, thereby undermining health status and increasing the risk of developing non-communicable diseases. According to the cited literature, athletes experience nasal symptoms more frequently than non-athletic individuals. This highlights a need for risk assessment, prevention strategies, accurate diagnostic tools, and individuated treatment. This review aims to evaluate the current state of knowledge regarding chronic upper respiratory conditions in athletes and explore their clinical impact. Further examination into pathophysiology, consequences, and optimal treatment strategies is necessary. Ultimately, creating robust, evidence-based guidelines for healthcare professionals regarding chronic upper respiratory conditions in athletes should be considered.

23 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
PSPiotr Sobkiewicz
Piotr Sobkiewicz
MGMartyna Grodzińska
Martyna Grodzińska
KPKarol Poplicha
Karol Poplicha
MUMaria Ufniarska
Maria Ufniarska
APAleksandra Piech
Aleksandra Piech
JUJarosław Ucieklak
Jarosław Ucieklak
Introduction: Gastric cancer (GC) remains a major global health issue, ranking among the leading causes of cancer-related deaths worldwide. Despite improvements in diagnostic methods, many patients are still diagnosed at an advanced stage. The discovery of HER2 overexpression in approximately 15–20% of GC cases introduced targeted therapy into clinical practice. The ToGA trial established trastuzumab combined with chemotherapy as the first-line treatment for HER2-positive advanced GC, significantly improving survival. Aim of the study: This review summarizes current knowledge about the epidemiology, clinical staging, and treatment strategies for advanced gastric cancer, with particular focus on HER2-positive tumors. It also outlines the evolution of HER2-targeted therapies and discusses novel agents and clinical trials that may shape future management. Material and methods: The review was based on data collected from PubMed and Google Scholar using key terms: gastric cancer, HER2-positive, chemotherapy, targeted therapy, immunotherapy, clinical trials, ToGA, T-DXd, ZW25, KN026. Conclusion: GC is a complex and heterogeneous disease that requires accurate staging and individualized treatment strategies. While traditional chemotherapy remains the foundation of care, the incorporation of targeted therapies and immune checkpoint inhibitors has changed the treatment landscape. HER2 remains a critical biomarker, with newer agents such as trastuzumab deruxtecan, zanidatamab, and KN026 showing promising results. Continued molecular profiling and participation in clinical trials are essential for improving outcomes in HER2-positive GC patients.